Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate
- PMID: 10669351
- DOI: 10.1086/315285
Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate
Abstract
Two animal models were used to study maternal transfer of antibody to a group B Streptococcus (GBS) type III polysaccharide-tetanus toxoid (III-TT) conjugate. The III-TT vaccine protected all 27 mouse pups born to vaccinated dams against a GBS challenge. In a separate study of vaccinated mouse dams and pups, maternal sera contained all 4 subclasses of polysaccharide-specific IgG, with IgG1 accounting for 83% of total IgG. Specific IgG subclass distribution (IgG1>>IgG2a=IgG2b=IgG3) in newborn pups closely resembled that in their mothers. Seven of 9 female baboons given the III-TT vaccine had 5- to 36-fold increases in specific antibody from baseline levels; they transferred 26%-185% of specific antibody to their offspring. Matched maternal and neonatal sera obtained at delivery were functionally equivalent in an in vitro opsonophagocytosis assay. These preclinical studies provide further evidence for effective immunogenicity of GBS conjugate vaccine and efficient transport of functionally active maternal antibody.
Similar articles
-
Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.J Infect Dis. 1999 Sep;180(3):892-5. doi: 10.1086/314955. J Infect Dis. 1999. PMID: 10438388
-
Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.J Infect Dis. 1999 Jan;179(1):142-50. doi: 10.1086/314574. J Infect Dis. 1999. PMID: 9841833 Clinical Trial.
-
Conjugate vaccines against group B Streptococcus types IV and VII.J Infect Dis. 2002 Jul 1;186(1):123-6. doi: 10.1086/341073. Epub 2002 Jun 14. J Infect Dis. 2002. PMID: 12089673
-
Vaccines for other neonatal infections: are group B streptococcal infections vaccine-preventable?Expert Rev Vaccines. 2004 Aug;3(4):371-4. doi: 10.1586/14760584.3.4.371. Expert Rev Vaccines. 2004. PMID: 15270637 Review.
-
An update on vaccination against group B streptococcus.Expert Rev Vaccines. 2011 May;10(5):685-94. doi: 10.1586/erv.11.61. Expert Rev Vaccines. 2011. PMID: 21604988 Review.
Cited by
-
Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.Vaccine. 2022 Oct 6;40(42):6107-6113. doi: 10.1016/j.vaccine.2022.09.018. Epub 2022 Sep 15. Vaccine. 2022. PMID: 36115800 Free PMC article.
-
The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.Vaccine. 2019 May 27;37(24):3190-3198. doi: 10.1016/j.vaccine.2019.04.039. Epub 2019 Apr 25. Vaccine. 2019. PMID: 31031031 Free PMC article. Review.
-
Lymphocyte modulation in a baboon model of immunosenescence.Clin Diagn Lab Immunol. 2003 Sep;10(5):870-5. doi: 10.1128/cdli.10.5.870-875.2003. Clin Diagn Lab Immunol. 2003. PMID: 12965919 Free PMC article.
-
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.F1000Res. 2016 Sep 22;5:2355. doi: 10.12688/f1000research.9363.1. eCollection 2016. F1000Res. 2016. PMID: 27803803 Free PMC article. Review.
-
Vaccines for Streptococcus agalactiae: current status and future perspectives.Front Immunol. 2024 Jun 14;15:1430901. doi: 10.3389/fimmu.2024.1430901. eCollection 2024. Front Immunol. 2024. PMID: 38947337 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical